Amneal Pharmaceuticals (AMRX) announced that the U.S. Food and Drug Administration has approved the Company’s Abbreviated New Drug Application for bimatoprost ophthalmic solution 0.01%. The product is the generic equivalent of LUMIGAN 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company. Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals price target raised to $14 from $12 at JPMorgan
- Amneal Pharmaceuticals receives FDA approval of sodium oxybate oral solution
- Amneal gets FDA approval for risperidone extended-release injectable suspension
- Amneal Pharma Reports Strong Q2 2025 Results
- Amneal Pharma’s Optimistic Q2 Earnings Call Highlights